Oklahoma, the first state to launch an outcomes-based pricing program under its Medicaid program, is about to announce its third drug contract with a drug manufacturer, coming as at least two other states weigh launching similar value-based programs to cut drug costs, sources tell Inside Health Policy . Oklahoma’s contracts stipulate that if patients using the medications do not meet specified benchmarks, manufacturers could be on the hook for paying additional rebates. In return, the drugs are more accessible for...